Short Interest in Evotec AG (NASDAQ:EVO) Decreases By 46.7%

Evotec AG (NASDAQ:EVO) saw a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 28,249 shares, a decrease of 46.7% from the June 30th total of 53,014 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 65,895 shares, the days-to-cover ratio is presently 0.4 days.

Evotec Stock Down 0.5%

Shares of NASDAQ EVO traded down $0.01 during trading hours on Wednesday, reaching $1.95. 59,645 shares of the stock were exchanged, compared to its average volume of 99,251. The stock’s fifty day simple moving average is $2.63 and its 200 day simple moving average is $2.95. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.68 and a quick ratio of 1.60. Evotec has a 52 week low of $1.91 and a 52 week high of $4.31.

Institutional Trading of Evotec

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Apollon Wealth Management LLC acquired a new position in Evotec in the 1st quarter valued at $28,000. BNP Paribas Financial Markets lifted its position in Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after purchasing an additional 4,600 shares during the period. Bank of America Corp DE grew its stake in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Evotec in the 4th quarter valued at approximately $40,000. Finally, XTX Topco Ltd bought a new stake in shares of Evotec during the 2nd quarter worth approximately $66,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Analyst Ratings Changes

EVO has been the subject of a number of research analyst reports. Berenberg Bank cut Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. Wall Street Zen lowered Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. HC Wainwright dropped their price target on Evotec from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, July 15th. TD Cowen cut Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research note on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a report on Tuesday, July 21st. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.00.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.